Bei Akademie registrieren
Hengrui Medicine stock, FDA approval

Hengrui Medicine stock: FDA accepts camrelizumab filing

Published on 11/06/2026 at 01:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hengrui Medicine stock faces a new regulatory milestone after the FDA accepted a resubmitted camrelizumab filing. A decision is targeted for April 2027.

Regulatory milestone for Hengrui

  • The FDA accepted Hengrui's resubmitted biologics application for camrelizumab in combination with apatinib for first-line treatment of unresectable or metastatic liver cancer.
  • The target FDA review date is April 9, 2027, keeping the program on the regulatory agenda for investors.
  • Hengrui's recent results showed stronger innovative-drug sales and licensing income alongside continued pipeline development.
Hengrui Medicine stock, FDA approval, camrelizumab, oncology, China pharmaceuticals, Illustration mit AI erstellt.
Hengrui Medicine stock, FDA approval, camrelizumab, oncology, China pharmaceuticals, Illustration mit AI erstellt.

Hengrui Pharma reached a new regulatory milestone on November 4, 2026, when the U.S. Food and Drug Administration accepted its resubmitted biologics license application for camrelizumab. The filing covers first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma in combination with apatinib mesylate tablets, according to Futubull.

The FDA set April 9, 2027, as the target review date. The indication had previously received orphan drug designation, while Hengrui said cumulative research and development investment in the related project was approximately RMB 3.533 billion.

Pipeline adds regulatory optionality

The filing gives investors a defined regulatory event to monitor, but acceptance does not guarantee approval or commercial launch. The program is part of Hengrui's broader effort to expand its innovative-medicine portfolio beyond China.

Hengrui's first-nine-month results, released on October 27, showed revenue of RMB 24.41 billion, up 5.26 percent year over year, and net profit attributable to shareholders of RMB 6.92 billion, up 20.38 percent. Innovative-drug sales rose 17.05 percent to RMB 13.87 billion, while revenue from out-licensing innovative drugs reached RMB 2.78 billion, according to Hengrui Pharma's release carried by PR Newswire.

Hengrui's pharmaceutical focus

Hengrui develops innovative medicines and maintains research programs across oncology, chronic diseases and other therapeutic areas. Its strategy combines domestic development with international licensing and commercialization partnerships. The company is a China-based pharmaceutical developer seeking broader reach through clinical progress and overseas collaborations.

For investors, the next milestones include the FDA review of the camrelizumab application and further conversion of Hengrui's pipeline into approved products and licensing transactions.

Hengrui Medicine key facts

  • Company: Hengrui Pharma
  • Regulatory event: FDA acceptance of a resubmitted camrelizumab biologics application
  • Indication: First-line treatment of unresectable or metastatic hepatocellular carcinoma with apatinib
  • Target review date: April 9, 2027
  • Research and development investment: Approximately RMB 3.533 billion for the related project
Disclaimer...
en | boerse | 70466936 |